Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70


cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies.

Li Y, Hamlin DK, Chyan MK, Wong R, Dorman EF, Emery RC, Woodle DR, Manger RL, Nartea M, Kenoyer AL, Orozco JJ, Green DJ, Press OW, Storb R, Sandmaier BM, Wilbur DS.

PLoS One. 2018 Oct 18;13(10):e0205135. doi: 10.1371/journal.pone.0205135. eCollection 2018.


CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.

Green DJ, O'Steen S, Lin Y, Comstock ML, Kenoyer AL, Hamlin DK, Wilbur DS, Fisher DR, Nartea M, Hylarides MD, Gopal AK, Gooley TA, Orozco JJ, Till BG, Orcutt KD, Wittrup KD, Press OW.

Blood. 2018 Feb 8;131(6):611-620. doi: 10.1182/blood-2017-09-807610. Epub 2017 Nov 20.


Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

O'Steen S, Green DJ, Gopal AK, Orozco JJ, Kenoyer AL, Lin Y, Wilbur DS, Hamlin DK, Fisher DR, Hylarides MD, Gooley TA, Waltman A, Till BG, Press OW.

Cancer Res. 2017 Jul 15;77(14):3885-3893. doi: 10.1158/0008-5472.CAN-17-0082. Epub 2017 May 31.


An automated flow system incorporating in-line acid dissolution of bismuth metal from a cyclotron irradiated target assembly for use in the isolation of astatine-211.

O'Hara MJ, Krzysko AJ, Niver CM, Morrison SS, Owsley SL Jr, Hamlin DK, Dorman EF, Scott Wilbur D.

Appl Radiat Isot. 2017 Apr;122:202-210. doi: 10.1016/j.apradiso.2017.02.001. Epub 2017 Feb 2.


Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.

Green DJ, Frayo SL, Lin Y, Hamlin DK, Fisher DR, Frost SH, Kenoyer AL, Hylarides MD, Gopal AK, Gooley TA, Orozco JJ, Till BG, O'Steen S, Orcutt KD, Wilbur DS, Wittrup KD, Press OW.

Cancer Res. 2016 Nov 15;76(22):6669-6679. doi: 10.1158/0008-5472.CAN-16-0571. Epub 2016 Sep 2.


Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.

Orozco JJ, Kenoyer A, Balkin ER, Gooley TA, Hamlin DK, Wilbur DS, Hylarides MD, Frost SH, Mawad R, O'Donnell P, Sandmaier BM, Fuchs EJ, Luznik L, Green DJ, Gopal AK, Press OW, Pagel JM.

Blood. 2016 Jan 21;127(3):352-9. doi: 10.1182/blood-2014-12-617019. Epub 2015 Nov 17.


α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation.

Frost SH, Miller BW, Bäck TA, Santos EB, Hamlin DK, Knoblaugh SE, Frayo SL, Kenoyer AL, Storb R, Press OW, Wilbur DS, Pagel JM, Sandmaier BM.

J Nucl Med. 2015 Nov;56(11):1766-73. doi: 10.2967/jnumed.115.162388. Epub 2015 Sep 3.


Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.

Miller BW, Frost SH, Frayo SL, Kenoyer AL, Santos E, Jones JC, Green DJ, Hamlin DK, Wilbur DS, Fisher DR, Orozco JJ, Press OW, Pagel JM, Sandmaier BM.

Med Phys. 2015 Jul;42(7):4094-105. doi: 10.1118/1.4921997.


(211)Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy.

Burtner CR, Chandrasekaran D, Santos EB, Beard BC, Adair JE, Hamlin DK, Wilbur DS, Sandmaier BM, Kiem HP.

Hum Gene Ther. 2015 Jun;26(6):399-406. doi: 10.1089/hum.2015.021.


Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.

Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, Hamlin DK, Wilbur DS, Balkan ER, Lin Y, Miller BW, Frost SH, Gopal AK, Orozco JJ, Gooley TA, Laird KL, Till BG, Bäck T, Sandmaier BM, Pagel JM, Press OW.

Blood. 2015 Mar 26;125(13):2111-9. doi: 10.1182/blood-2014-11-612770. Epub 2015 Jan 27.


Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.

Orozco JJ, Balkin ER, Gooley TA, Kenoyer A, Hamlin DK, Wilbur DS, Fisher DR, Hylarides MD, Shadman M, Green DJ, Gopal AK, Press OW, Pagel JM.

PLoS One. 2014 Dec 2;9(12):e113601. doi: 10.1371/journal.pone.0113601. eCollection 2014.


A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

Green DJ, Orgun NN, Jones JC, Hylarides MD, Pagel JM, Hamlin DK, Wilbur DS, Lin Y, Fisher DR, Kenoyer AL, Frayo SL, Gopal AK, Orozco JJ, Gooley TA, Wood BL, Bensinger WI, Press OW.

Cancer Res. 2014 Feb 15;74(4):1179-89. doi: 10.1158/0008-5472.CAN-13-1589. Epub 2013 Dec 26.


Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.

Orozco JJ, Bäck T, Kenoyer A, Balkin ER, Hamlin DK, Wilbur DS, Fisher DR, Frayo SL, Hylarides MD, Green DJ, Gopal AK, Press OW, Pagel JM.

Blood. 2013 May 2;121(18):3759-67. doi: 10.1182/blood-2012-11-467035. Epub 2013 Mar 7.


Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation.

Chen Y, Kornblit B, Hamlin DK, Sale GE, Santos EB, Wilbur DS, Storer BE, Storb R, Sandmaier BM.

Blood. 2012 Feb 2;119(5):1130-8. doi: 10.1182/blood-2011-09-380436. Epub 2011 Dec 1.


Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.

Park SI, Shenoi J, Frayo SM, Hamlin DK, Lin Y, Wilbur DS, Stayton PS, Orgun N, Hylarides M, Buchegger F, Kenoyer AL, Axtman A, Gopal AK, Green DJ, Pagel JM, Press OW.

Clin Cancer Res. 2011 Dec 1;17(23):7373-82. doi: 10.1158/1078-0432.CCR-11-1204. Epub 2011 Oct 5.


Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.

Pagel JM, Kenoyer AL, Bäck T, Hamlin DK, Wilbur DS, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N, Orozco J, Shenoi J, Lin Y, Gopal AK, Green DJ, Appelbaum FR, Press OW.

Blood. 2011 Jul 21;118(3):703-11. doi: 10.1182/blood-2011-04-347039. Epub 2011 May 25.


Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention.

Wilbur DS, Chyan MK, Hamlin DK, Nguyen H, Vessella RL.

Bioconjug Chem. 2011 Jun 15;22(6):1089-102. doi: 10.1021/bc1005625. Epub 2011 May 5.


Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.

Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T, Lin Y, Fisher DR, Gopal AK, Green DJ, Press OW.

Blood. 2010 Nov 18;116(20):4231-9. doi: 10.1182/blood-2010-05-282327. Epub 2010 Aug 11.


Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.

Wilbur DS, Park SI, Chyan MK, Wan F, Hamlin DK, Shenoi J, Lin Y, Wilbur SM, Buchegger F, Pantelias A, Pagel JM, Press OW.

Bioconjug Chem. 2010 Jul 21;21(7):1225-38. doi: 10.1021/bc100030q.


Pilot study of a (213)bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation.

Nakamae H, Kerbauy FR, Wilbur DS, Bethge W, Hamlin DK, Santos EB, Storb R, Sandmaier BM.

Transplantation. 2010 Jun 15;89(11):1336-40. doi: 10.1097/TP.0b013e3181d98c3d.


Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues.

Wilbur DS, Chyan MK, Hamlin DK, Perry MA.

Nucl Med Biol. 2010 Feb;37(2):167-78. doi: 10.1016/j.nucmedbio.2009.10.004.


Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.

Wilbur DS, Thakar MS, Hamlin DK, Santos EB, Chyan MK, Nakamae H, Pagel JM, Press OW, Sandmaier BM.

Bioconjug Chem. 2009 Oct 21;20(10):1983-91. doi: 10.1021/bc9000799. Epub 2009 Sep 4.


Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.

Green DJ, Pagel JM, Nemecek ER, Lin Y, Kenoyer A, Pantelias A, Hamlin DK, Wilbur DS, Fisher DR, Rajendran JG, Gopal AK, Park SI, Press OW.

Blood. 2009 Aug 6;114(6):1226-35. doi: 10.1182/blood-2009-03-210344. Epub 2009 Jun 10.


Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.

Nakamae H, Wilbur DS, Hamlin DK, Thakar MS, Santos EB, Fisher DR, Kenoyer AL, Pagel JM, Press OW, Storb R, Sandmaier BM.

Cancer Res. 2009 Mar 15;69(6):2408-15. doi: 10.1158/0008-5472.CAN-08-4363. Epub 2009 Feb 24.


A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.

Pagel JM, Orgun N, Hamlin DK, Wilbur DS, Gooley TA, Gopal AK, Park SI, Green DJ, Lin Y, Press OW.

Blood. 2009 May 14;113(20):4903-13. doi: 10.1182/blood-2008-11-187401. Epub 2009 Jan 5.


Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.

Pagel JM, Matthews DC, Kenoyer A, Hamlin DK, Wilbur DS, Fisher DR, Gopal AK, Lin Y, Saganic L, Appelbaum FR, Press OW.

Cancer Res. 2009 Jan 1;69(1):185-92. doi: 10.1158/0008-5472.CAN-08-2513.


Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.

Pagel JM, Hedin N, Drouet L, Wood BL, Pantelias A, Lin Y, Hamlin DK, Wilbur DS, Gopal AK, Green D, Appelbaum FR, Press OW.

Blood. 2008 Feb 15;111(4):2261-8. Epub 2007 Nov 27.


Pretargeted radioimmunotherapy for B-cell lymphomas.

Green DJ, Pagel JM, Pantelias A, Hedin N, Lin Y, Wilbur DS, Gopal A, Hamlin DK, Press OW.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5598s-5603s. Review.


211AtCl@US-tube nanocapsules: a new concept in radiotherapeutic-agent design.

Hartman KB, Hamlin DK, Wilbur DS, Wilson LJ.

Small. 2007 Sep;3(9):1496-9. No abstract available.


Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination.

Wilbur DS, Chyan MK, Hamlin DK, Vessella RL, Wedge TJ, Hawthorne MF.

Bioconjug Chem. 2007 Jul-Aug;18(4):1226-40. Epub 2007 Jun 21.


Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.

Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, Axworthy D, Hamlin DK, Wilbur DS, Gopal AK, Press OW.

Cancer Res. 2007 Jun 15;67(12):5921-8.


Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas.

Pantelias A, Pagel JM, Hedin N, Saganic L, Wilbur S, Hamlin DK, Wilbur DS, Lin Y, Stone D, Axworthy D, Gopal AK, Press OW.

Blood. 2007 Jun 1;109(11):4980-7. Epub 2007 Feb 15.


Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.

Pagel JM, Lin Y, Hedin N, Pantelias A, Axworthy D, Stone D, Hamlin DK, Wilbur DS, Press OW.

Blood. 2006 Jul 1;108(1):328-36. Epub 2006 Mar 23.


Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model.

Nemecek ER, Hamlin DK, Fisher DR, Krohn KA, Pagel JM, Appelbaum FR, Press OW, Matthews DC.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):787-94.


Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.

Hamblett KJ, Press OW, Meyer DL, Hamlin DK, Axworthy D, Wilbur DS, Stayton PS.

Bioconjug Chem. 2005 Jan-Feb;16(1):131-8.


Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study.

Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW, Sandmaier BM.

Transplantation. 2004 Aug 15;78(3):352-9.


Biotin reagents in antibody pretargeting. 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl- and nido-carboranyl-biotin derivatives.

Wilbur DS, Hamlin DK, Chyan MK, Kegley BB, Quinn J, Vessella RL.

Bioconjug Chem. 2004 May-Jun;15(3):601-16.


Synthesis, radioiodination, and biodistribution of some nido- and closo-monocarbon carborane derivatives.

Wilbur DS, Hamlin DK, Srivastava RR, Chyan MK.

Nucl Med Biol. 2004 May;31(4):523-30.


Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds.

Wilbur DS, Chyan MK, Hamlin DK, Kegley BB, Risler R, Pathare PM, Quinn J, Vessella RL, Foulon C, Zalutsky M, Wedge TJ, Hawthorne MF.

Bioconjug Chem. 2004 Jan-Feb;15(1):203-23.


Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.

Subbiah K, Hamlin DK, Pagel JM, Wilbur DS, Meyer DL, Axworthy DB, Mallett RW, Theodore LJ, Stayton PS, Press OW.

J Nucl Med. 2003 Mar;44(3):437-45.


Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation.

Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW, Fisher DR, Sandmaier BM.

Blood. 2003 Jun 15;101(12):5068-75. Epub 2003 Feb 27.


Trifunctional conjugation reagents. Reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies.

Wilbur DS, Chyan MK, Hamlin DK, Kegley BB, Nilsson R, Sandberg BE, Brechbiel M.

Bioconjug Chem. 2002 Sep-Oct;13(5):1079-92.


Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts.

Sandmaier BM, Bethge WA, Wilbur DS, Hamlin DK, Santos EB, Brechbiel MW, Fisher DR, Storb R.

Blood. 2002 Jul 1;100(1):318-26.


Streptavidin in antibody pretargeting. 3. Comparison of biotin binding and tissue localization of 1,2-cyclohexanedione and succinic anhydride modified recombinant streptavidin.

Wilbur DS, Hamlin DK, Meyer DL, Mallett RW, Quinn J, Vessella RL, Press OW.

Bioconjug Chem. 2002 May-Jun;13(3):611-20.


A streptavidin-biotin binding system that minimizes blocking by endogenous biotin.

Hamblett KJ, Kegley BB, Hamlin DK, Chyan MK, Hyre DE, Press OW, Wilbur DS, Stayton PS.

Bioconjug Chem. 2002 May-Jun;13(3):588-98.


Supplemental Content

Loading ...
Support Center